Alector, Inc.
About Alector, Inc.
Alector Inc is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases. The company advances a pipeline of product candidates including Nivisnebart (AL101/GSK4527226) for Alzheimer's disease, AL137 for Alzheimer's disease, AL050 for Parkinson's disease and Lewy body dementia, and AL064, an siRNA program targeting tau for Alzheimer's disease and other tauopathies, supported by its proprietary Alector Brain Carrier (ABC) platform designed to improve delivery of therapeutics across the blood-brain barrier.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $21.0M
- Net income
- -$142.9M
- Total assets
- $293.2M
- Market cap
- $181.5M
- Operating margin
- -741.3%
- Net margin
- -679.2%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $21.0M
- Operating expenses
- $177.1M
- Operating income
- -$156.0M
- Income tax
- $168.0K
- Net income
- -$142.9M
- EPS (basic)
- $-1.39
- EPS (diluted)
- $-1.39
Balance sheet
- Total assets
- $293.2M
- Current assets
- $266.5M
- Total liabilities
- $262.6M
- Current liabilities
- $69.5M
- Shareholders’ equity
- $30.6M
Cash flow
- Operating cash flow
- -$184.0M
- Investing cash flow
- $196.6M
- Financing cash flow
- $20.2M
- Net cash flow
- $32.8M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $181.5M
- EPS (diluted)
- $-1.39
- Shares outstanding
- 110.7M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Feb 7, 2019
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $142.9M in FY2025.
- Revenue declined 90% from FY2021 to FY2025.
- Trading 51% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Alector, Inc..
Write a review
News about Alector, Inc.
News & sentiment via Polygon.io
